CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 99 enrolled
Drug / intervention
Ketamine and Placebodrug
Likely dose
Ketamine and Placebo 0.23 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00588952
NCT00588952N/ACompleted
CompareCT.gov

NMDA Dysregulation in Individuals With a Family Vulnerability to Alcoholism

Yale University·interventional·Posted Jan 9, 2008·Updated Oct 6, 2021

In Brief

A clinical study evaluating Ketamine and Placebo for Alcoholism. Completed, enrolled 99 participants across 1 site.

Detailed Summary

The proposed study is the first to explore the contribution of brain glutamate systems, a major target of ethanol in the brain, to the vulnerability to develop alcoholism. This study may lead to an enhanced understanding of the underlying neurobiological mechanism in high-risk individuals that may lead to the transition from moderate to excessive use of alcohol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsVA Connecticut Healthcare System, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 9, 2008
Enrollment StartMar 1, 2001
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 14.3 yearsPosted 18.5 years ago

Interventions

Ketamine and Placebodrug

Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes